Three Rivers Announces Positive Results from Phase 3 DIRECT Trial of Once-Daily INFERGEN(R) with Ribavirin in Hepatitis C Virus Treatmen...(fit from retreatment with INFERGEN and R...)

About Consensus Interferon (INFERGEN(R))

Consensus Interferon or INFERGEN(R) is a unique, bio-optimized, selective and highly potent type 1 interferon alpha. INFERGEN is indicated for the treatment of chronic HCV infection in patients 18 years of age or older with compensated liver disease who have anti-HCV serum antibodies and /or the presence of HCV RNA. INFERGEN is currently FDA approved for TIW monotherapy dosing in naive and previous treatment failure patients.

Important Safety Information

Physicians and patients can obtain additional prescribing information regarding INFERGEN, including the product's safety profile and the box warning for all interferon alphas regarding neuropsychiatric, autoimmune, ischemic and infectious disorders, by visiting www.infergen.com.

About Hepatitis C

Hepatitis means inflammation of the liver. Hepatitis C is a liver disease that results from infection with the hepatitis C virus. It can range in severity from a mild illness lasting a few weeks to a serious, lifelong illness. Hepatitis C can be either "acute" or "chronic." Acute hepatitis C virus infection is a short-term illness that occurs within the first 6 months after someone is exposed to the hepatitis C virus. For most people, acute infection leads to chronic infection. Chronic hepatitis C is a serious disease than can result in long-term health problems, or even death. There is no vaccine for hepatitis C.

About Three Rivers Pharmaceuticals

Three Rivers Pharmaceuticals is a privately held company headquartered in Warrendale, Pennsylvania that focuses on specialized therapies including hepatitis C therapies. More information ab
'/>"/>